PERSPECTA

News from every angle

← Back to headlines

Alx Oncology Presents Interim ASPEN-09 Clinical Trial Data

Alx Oncology has provided an update on interim data from its ASPEN-09 clinical trial, involving approximately 80 patients, with a focus on the CD47-high cohort showing a 22-month median progression-free survival.

9 May, 08:02 — 9 May, 08:02
PostShare

Sources

Showing 1 of 1 sources
seeking-alphaMixed1h ago

Alx Oncology outlines interim ASPEN-09 data from ~80 patients by mid-2027 as CD47-high cohort shows 22-month median PFS

Read full article →

Related Stories

'Astronauts back on Earth': Artemis II crew splashes down after record-breaking moon flyby – video

just now

Taal Volcano Exhibits Continued Seismic Activity After Minor Eruption

just now

New Wasp Species Named After David Attenborough

1h ago

GalaxEye's Drishti Satellite: A First of Its Kind

1h ago